A01K 2267/0362
Animal model for lipid/glucose metabolism
Official title: Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
A01K2267/0362 (Animal model for lipid/glucose metabolism) appears on 287 US grants and 474 published applications in this corpus.
Search patents in A01K- Granted patents
- 287
- Published applications
- 474
- Assignees
- 316
- Inventors
- 983
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 6 | 0 |
| 1998 | 10 | 0 |
| 1999 | 7 | 0 |
| 2000 | 6 | 0 |
| 2001 | 12 | 4 |
| 2002 | 7 | 19 |
| 2003 | 16 | 32 |
| 2004 | 5 | 10 |
| 2005 | 7 | 23 |
| 2006 | 7 | 20 |
| 2007 | 9 | 17 |
| 2008 | 7 | 24 |
| 2009 | 5 | 25 |
| 2010 | 7 | 19 |
| 2011 | 17 | 17 |
| 2012 | 15 | 15 |
| 2013 | 8 | 13 |
| 2014 | 13 | 14 |
| 2015 | 15 | 18 |
| 2016 | 7 | 17 |
| 2017 | 6 | 13 |
| 2018 | 7 | 16 |
| 2019 | 9 | 25 |
| 2020 | 10 | 19 |
| 2021 | 12 | 21 |
| 2022 | 12 | 20 |
| 2023 | 10 | 33 |
| 2024 | 8 | 17 |
| 2025 | 10 | 15 |
| 2026 | 10 | 8 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Fullerenes to treat diseases and conditions25 Aug 2026US 12,714,679 B2The Cleveland Clinic Foundation
- Compositions comprising miR-690 and methods therefor16 Jun 2026US 12,653,783 B2The Regents of the University of California
- Compositions and methods for regulating fatty acids26 May 2026US 12,637,695 B2Shriners Hospitals for Children
- Compositions for the treatment of Fabry disease19 May 2026US 12,630,839 B2Sangamo Therapeutics, Inc.
- Compositions useful for treating GM1 gangliosidosis7 Apr 2026US 12,594,327 B2The Trustees of the University of Pennylvania
- Method for gene regulation and use thereof23 Jul 2026US 2026/0206728 A1Peking University
- Long non-coding rna lipter preserves lipid metabolism of the human heart16 Jul 2026US 2026/0201372 A1The Trustees of Indiana University
- Transcription modulation in animals using crispr/cas systems16 Jul 2026US 2026/0201410 A1Regeneron Pharmaceuticals, Inc.
- Non-hla matched humanized nsg mouse model with patient-derived xenograft2 Jul 2026US 2026/0185119 A1The Jackson Laboratory
- Viral expression construct comprising a fibroblast growth factor (fgf21) coding sequence21 May 2026US 2026/0139021 A1Universitat Autonoma De Barcelona
Most cited
By later US patents
- Growth hormone antagonists389US 5,350,836 AOhio University · 1994
- Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same147US 6,656,475 B1The Johns Hopkins University School of Medicine · 2003
- Transgenic non-human animals expressing a truncated activintype II receptor117US 6,891,082 B2The Johns Hopkins University School of Medicine · 2005
- Therapeutic uses of inhibitors of RTP80198US 7,741,299 B2Quark Pharmaceuticals, Inc. · 2010
- Transgenic mouse for targeted recombination mediated by modified Cre-ER97US 7,112,715 B2Gie-Cerbm, Centre Europeen de Recherche en Biologie et en Medecine (GIE) · 2006